---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-032662"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:52:03.725285+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma: INTASYL PH-762 shows 100% tumor clearance in one cSCC patient; SMC clearance safe

## Summary
- 100% pathologic complete response in 1 of 3 cSCC patients at Day 36 in final dose cohort; >90% clearance in second, >50% in third.
- Safety Monitoring Committee issued favorable review, no dose-limiting toxicities at max dose; PH-762 well tolerated across 5 cohorts.
- Cumulative Phase 1b data: 6 complete, 2 near-complete, 2 partial responses among 16 cSCC patients; no clinical progression.
- CEO notes PH-762 is promising non-surgical alternative for cutaneous carcinomas; trial continues to screen additional patients.

## SEC filing metadata
- accession: 0001437749-25-032662
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774925032662/0001437749-25-032662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774925032662/phio20251023_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-032662
- JSON: https://secwatch.observer/filing/0001437749-25-032662.json
- Plain text: https://secwatch.observer/filing/0001437749-25-032662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.